ALK-Abello A/S
CSE:ALK B
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
ALK-Abello A/S
CSE:ALK B
|
DK |
ALK-Abello A/S
ALK-Abello makes allergy treatment medicines and testing products. Its main business is allergy immunotherapy, which helps patients become less sensitive to things like pollen, dust mites, and animal allergens over time. It also sells allergy diagnostics used by doctors and clinics to identify what triggers a patient’s symptoms. The company sells through healthcare channels rather than directly to everyday shoppers. Its customers include doctors, allergy specialists, hospitals, clinics, pharmacies, and distributors in different countries. ALK-Abello earns money by selling prescription allergy tablets and drops, injection-based allergy treatments, and diagnostic products used in medical practice. What makes ALK-Abello different is that it sits in a narrow part of the drug market focused on the causes of allergies, not just symptom relief. Its products are used over long treatment periods and require medical guidance, which creates a specialized relationship with doctors and health systems. That makes the company more like a focused allergy platform than a broad drugmaker.
ALK-Abello makes allergy treatment medicines and testing products. Its main business is allergy immunotherapy, which helps patients become less sensitive to things like pollen, dust mites, and animal allergens over time. It also sells allergy diagnostics used by doctors and clinics to identify what triggers a patient’s symptoms.
The company sells through healthcare channels rather than directly to everyday shoppers. Its customers include doctors, allergy specialists, hospitals, clinics, pharmacies, and distributors in different countries. ALK-Abello earns money by selling prescription allergy tablets and drops, injection-based allergy treatments, and diagnostic products used in medical practice.
What makes ALK-Abello different is that it sits in a narrow part of the drug market focused on the causes of allergies, not just symptom relief. Its products are used over long treatment periods and require medical guidance, which creates a specialized relationship with doctors and health systems. That makes the company more like a focused allergy platform than a broad drugmaker.
Strong Growth: ALK delivered 18% organic revenue growth in Q3 with particularly robust tablet sales, up 29% globally and 27% in Europe.
Margin Expansion: EBIT margin rose sharply from 13% to 23%, driven by sales growth, better gross margins, and cost efficiencies.
Full-Year Outlook: Management confirmed its guidance for 14%–16% revenue growth and an EBIT margin of 19%–21% for 2024.
Strategic Deal: ALK signed its largest-ever in-licensing deal for neffy nasal spray, aiming to expand into new allergy segments and expects it to boost growth from 2025 onward.
China Setback: ALK is redesigning its clinical trial for the house dust mite tablet in China after withdrawing its application, with approval now targeted for 2028.
Pipeline Progress: Recruitment for the peanut allergy tablet Phase I/II trial is complete, with safety and tolerability data expected before year-end.
Restructuring Costs: One-off costs will occur in Q4 related to China, but these are not expected to impact 2025 numbers.
